



**Governing Council
Sixty-sixth Session**

GC/66/19
11 April 2024

Lyon, 15–16 May 2024
Hybrid format

APPOINTMENT OF NEW MEMBERS OF THE SCIENTIFIC COUNCIL

1. In accordance with Article VI of the Statute and Resolution [GC/62/R18](#), the term of office of five members of the Scientific Council, namely Drs Louisa Gordon (Australia), Marc Arbyn (Belgium), Manami Inoue (Japan), Ferrán Catalá (Spain) and Kalipso Chalkidou (UK) will be completed with the 2024 meeting of the Governing Council.

2. For the information of the Council, this leaves the following 21 members (7 women and 14 men) still serving on the Scientific Council: Drs Einas Abdulaziz Eid Al Kuwari (Qatar), Walter Berger (Austria), Jie He (China), Marie-Elise Parent (Canada), Luis Felipe Ribeiro Pinto (Brazil) and Mathilde Touvier (France) until 2025; Drs Jeanette Falck Winther (Denmark), Satish Gopal (USA), Sirpa Heinävaara (Finland), Valery Lemmens (Netherlands) and Ben Spycher (Switzerland) until 2026; and Drs Mohamed Berraho (Morocco), Valeriy V. Breder (Russian Federation), Roberta De Angelis (Italy), David Gisselsson Nord (Sweden), André Karch (Germany), István Kenessey (Hungary), Young-Woo Kim (Republic of Korea), Prashant Mathur (India), Pål Romundstad (Norway) and Orla Shiels (Ireland).

3. The areas of expertise of those members remaining on the Scientific Council are provided below for consideration by the Governing Council in making its selection of new Scientific Council members from among the nominations.

| Name | Country | Term of office | Gender | Field of expertise |
|-------------------------------|----------------|-----------------------|---------------|--|
| Einas Abdulaziz Eid Al Kuwari | Qatar | 2022 – 2025 | F | Pathology and laboratory medicine |
| Walter Berger | Austria | 2022 – 2025 | M | Systemic cancer therapy with a focus on primary brain tumours, thoracic malignancies and sarcomas 1) Identification of novel therapeutic molecular targets and the respective inhibitors 2) Development of tumour-targeted small molecule anticancer agents 3) Dissection of drug resistance mechanisms and development of circumvention approaches |
| Jie He | China | 2022 – 2025 | M | Thoracic cancer surgery, translational research of thoracic cancers |

| Name | Country | Term of office | Gender | Field of expertise |
|---------------------------|--------------------|----------------|--------|---|
| Marie-Elise Parent | Canada | 2022 – 2025 | F | Cancer epidemiology, with a focus on the etiological role of occupational, environmental and lifestyle factors |
| Luis Felipe Ribeiro Pinto | Brazil | 2022 – 2025 | M | Mechanisms of carcinogenesis; molecular epidemiology; epigenetics and somatic mutations in relation to etiological factors; developing biomarkers of early detection or targeted therapies in upper aerodigestive tract tumours |
| Mathilde Touvier | France | 2022 – 2025 | F | Epidemiology; nutrition and cancer |
| Jeanette Falck Winther | DK | 2023 – 2026 | F | Cancer treatment in survivors of childhood cancer; molecular/genetic profiles; radiation; familial cancer syndromes (neurofibromatosis type 1) affecting children. |
| Satish Gopal | USA | 2023 – 2026 | M | Lymphoid malignancies; HIV-associated malignancies; low- and middle-income countries; clinical/translational research; cancer epidemiology; outcomes research. |
| Sirpa Heinävaara | Finland | 2023 – 2026 | F | Statistics, modelling systems, cancer mortality, screening strategies, radiation epidemiology. |
| Valery Lemmens | NL | 2023 – 2026 | M | Cancer epidemiology; Cancer registration; Public health; Implementation science; Social inequalities; Global statistics. |
| Ben Spycher | Switzerland | 2023 – 2026 | M | Biostatistics, epidemiology, childhood cancer, environmental exposures. |
| Mohamed Berraho | Morocco | 2024 – 2027 | M | Cancer Epidemiology, epidemiology of cervical cancer, epidemiology of noncommunicable diseases (diabetes and hypertension), Epidemiology of NCD risk factors, mental health, occupational health. |
| Valeriy V. Breder | Russian Federation | 2024 – 2027 | M | Liver cancer: screening, early diagnosis, cancer treatment. Lung cancer: chemotherapy, immunotherapy, targeted therapy. |
| Roberta De Angelis | Italy | 2024 – 2027 | F | Descriptive and analytical cancer epidemiology; cancer registries; biostatistics; statistical methods to derive cancer burden and outcome indicators from population-based data. |

| Name | Country | Term of office | Gender | Field of expertise |
|------------------------|-------------------|----------------|--------|---|
| David Gisselsson Nord | Sweden | 2024 – 2027 | M | Genomics, childhood cancer, implementation of precision medicine, computational carcinogenesis, laboratory establishment in low-income countries. |
| André Karch | Germany | 2024 – 2027 | M | Causal inference in observational research, mammography screening, breast cancer, clinical epidemiology, biomarkers, statistical and epidemiological methods. |
| István Kenessey | Hungary | 2024 – 2027 | M | Epidemiology of cancer, cancer survivorship and the effect of advanced oncological therapies. |
| Young-Woo Kim | Republic of Korea | 2024 – 2027 | M | Surgical oncology (gastric cancer); translational research (proteogenomics and drug development); medical engineering for surgical device development and patient blood management. |
| Prashant Mathur | India | 2024 – 2027 | M | Noncommunicable diseases, epidemiology and surveillance (including cancer), cancer registrations, cancer risk reduction strategies. |
| Pål Richard Romundstad | Norway | 2024 – 2027 | M | Cancer epidemiology, reproductive epidemiology, mendelian randomization, life course and intergenerational studies. |
| Orla Sheils | Ireland | 2024 – 2027 | F | Molecular pathology; molecular diagnostic assays; translational research; virally driven cancers; cancer prevention, detection, diagnosis, and treatment. |

4. In accordance with Article VI.2 of the Agency’s Statute, the Governing Council is requested to select new members to be appointed to the Scientific Council from the attached list of experts, one each from Australia, Belgium, Japan, Spain, and UK.

| | |
|--|---|
| <p>AUSTRALIA</p> <p>Professor Adam Grant Elshaug Centre for Health Policy, Bouverie St University of Melbourne</p> <p>Field: Health policy (development, implementation, evaluation), health technology assessment and coverage, health economics and (clinical) epidemiology</p> | <p>BELGIUM</p> <p>Professor Jacques De Grève Consultant in the Medical Genetics Department of the UZ Brussel and Head of the Oncology Center of the UZ Brussels and Vrije Universiteit Brussel</p> <p>Field: Genomic-driven translational therapeutic studies and cancer genetics. cancer genomics, genetic cancer prevention, medicine and society.</p> <p style="text-align: center;">***</p> <p>Professor Eric Van Cutsem Professor Emeritus and Division head of Digestive Oncology, University Hospitals Gasthuisberg & University of Leuven.</p> <p>Field: Gastrointestinal and Digestive cancers (colorectal, gastric, pancreas, bile duct, esophageal cancer and neuroendocrine tumors),</p> |
| <p>JAPAN</p> <p>Professor Tatsuhiro Shibata Chief, Division of Cancer Genomics, National Cancer Center</p> <p>Field: Cancer genomics, tumour pathology, bioinformatics</p> <p style="text-align: center;">***</p> <p>Dr Norie Sawada Chief, Division of Cohort Research, National Cancer Center Institute for Cancer Control, Tokyo.</p> <p>Field: cancer epidemiology, cancer prevention for cancer control.</p> | <p>SPAIN</p> <p>Dr María José Sánchez Pérez Scientific Director of the Biomedical Research Institute of Granada</p> <p>Field: epidemiological studies and research projects related to the aetiology; patterns of care, and survival of cancer patients. Cancer epidemiology, cancer prevention (lifestyle, diet & nutrition) and control; EPIC coordinator</p> |

| | |
|--|--|
| <p>UK</p> <p>Professor Richard Sullivan King's College London & Guy's Hospital</p> <p>Field: Health economics, early detection (breast, cervix and oral cancer) lung cancer, global cancer surgery, cancer control (in particular populations impacted by insecurity and conflicts).</p> <p>***</p> <p>Professor Linda Sharp Institute of Health & Society, Newcastle University</p> <p>Field: Descriptive epidemiology, analytical epidemiology, cancer screening, early diagnosis. Particular interest in breast, gastrointestinal (colorectal, pancreas), head & neck, lung and brain cancers.</p> | |
|--|--|

NB: The *curricula vitae* will be distributed to Governing Council members only.